1. Home
  2. TBPH vs JFIN Comparison

TBPH vs JFIN Comparison

Compare TBPH & JFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • JFIN
  • Stock Information
  • Founded
  • TBPH 2013
  • JFIN 2011
  • Country
  • TBPH United States
  • JFIN China
  • Employees
  • TBPH N/A
  • JFIN N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • JFIN Finance: Consumer Services
  • Sector
  • TBPH Health Care
  • JFIN Finance
  • Exchange
  • TBPH Nasdaq
  • JFIN Nasdaq
  • Market Cap
  • TBPH 418.7M
  • JFIN 352.7M
  • IPO Year
  • TBPH N/A
  • JFIN 2019
  • Fundamental
  • Price
  • TBPH $9.47
  • JFIN $5.87
  • Analyst Decision
  • TBPH Buy
  • JFIN
  • Analyst Count
  • TBPH 4
  • JFIN 0
  • Target Price
  • TBPH $13.75
  • JFIN N/A
  • AVG Volume (30 Days)
  • TBPH 220.0K
  • JFIN 56.4K
  • Earning Date
  • TBPH 11-12-2024
  • JFIN 11-20-2024
  • Dividend Yield
  • TBPH N/A
  • JFIN 15.33%
  • EPS Growth
  • TBPH N/A
  • JFIN N/A
  • EPS
  • TBPH N/A
  • JFIN N/A
  • Revenue
  • TBPH $63,192,000.00
  • JFIN $854,955,021.00
  • Revenue This Year
  • TBPH $6.93
  • JFIN N/A
  • Revenue Next Year
  • TBPH $45.31
  • JFIN N/A
  • P/E Ratio
  • TBPH N/A
  • JFIN $1.90
  • Revenue Growth
  • TBPH 15.93
  • JFIN 21.87
  • 52 Week Low
  • TBPH $7.44
  • JFIN $4.00
  • 52 Week High
  • TBPH $11.71
  • JFIN $8.58
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 59.09
  • JFIN 35.84
  • Support Level
  • TBPH $9.38
  • JFIN $5.18
  • Resistance Level
  • TBPH $10.10
  • JFIN $6.85
  • Average True Range (ATR)
  • TBPH 0.35
  • JFIN 0.35
  • MACD
  • TBPH 0.06
  • JFIN -0.09
  • Stochastic Oscillator
  • TBPH 62.75
  • JFIN 41.32

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital + technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

Share on Social Networks: